Severity, Criticality, and Fatality of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Beta Variant.
Abu-Raddad, LJ; Chemaitelly, H
; Ayoub, HH; Yassine, HM; Benslimane, FM; Al Khatib, HA; Tang, P; Hasan, MR; Coyle, P; AlMukdad, S; +14 more...Al Kanaani, Z; Al Kuwari, E; Jeremijenko, A; Kaleeckal, AH; Latif, AN; Shaik, RM; Abdul Rahim, HF; Nasrallah, GK; Al Kuwari, MG; Butt, AA; Al Romaihi, HE; Al-Thani, MH; Al Khal, A; Bertollini, R and
(2021)
Severity, Criticality, and Fatality of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Beta Variant.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 75 (1).
e1188-e1191.
ISSN 1058-4838
DOI: 10.1093/cid/ciab909
Beta (B.1.351)-variant coronavirus disease 2019 (COVID-19) disease was investigated in Qatar. Compared with the Alpha (B.1.1.7) variant, odds (95% confidence interval) of progressing to severe disease, critical disease, and COVID-19-related death were 1.24-fold (1.11-1.39), 1.49-fold (1.13-1.97), and 1.57-fold (1.03-2.43) higher, respectively, for the Beta variant.
Item Type | Article |
---|---|
Elements ID | 166806 |
Date Deposited | 30 Nov 2021 17:58 |
ORCID: https://orcid.org/0000-0002-8756-6968